- Previous Close
56.40 - Open
55.72 - Bid 56.00 x --
- Ask 57.80 x --
- Day's Range
55.26 - 59.00 - 52 Week Range
42.95 - 137.00 - Volume
187,302 - Avg. Volume
223,108 - Market Cap (intraday)
40.186M - Beta (5Y Monthly) -1.77
- PE Ratio (TTM)
-- - EPS (TTM)
-0.52 - Earnings Date Sep 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The company was incorporated in 2006 and is based in Le Vésinet, France.
www.novacyt.comRecent News: NCYT.L
View MorePerformance Overview: NCYT.L
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NCYT.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NCYT.L
View MoreValuation Measures
Market Cap
42.25M
Enterprise Value
22.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.15
Price/Book (mrq)
0.57
Enterprise Value/Revenue
1.09
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-202.80%
Return on Assets (ttm)
-27.98%
Return on Equity (ttm)
-42.04%
Revenue (ttm)
18.56M
Net Income Avi to Common (ttm)
-37.36M
Diluted EPS (ttm)
-0.52
Balance Sheet and Cash Flow
Total Cash (mrq)
32.95M
Total Debt/Equity (mrq)
18.67%
Levered Free Cash Flow (ttm)
-38.13M